Artivion (AORT) Q1 2023: ONIX Platform Grows 24%, Fueling Raised Guidance and Margin Leverage
Artivion’s Q1 saw ONIX platform growth outpace expectations, enabling a guidance raise and heightening margin leverage prospects for 2023 and beyond. Commercial execution in APAC and Latin America, regulatory catalysts, and pricing power in proprietary devices position the company for sustained double-digit growth. With supply chain improvements and PMA trial progress, Artivion’s business model is set for both operational and financial expansion.
Summary
- ONIX Platform Outperformance: Double-digit ONIX growth and pricing power reinforce Artivion’s market differentiation.
- Emerging Market Expansion: APAC and Latin America growth rates outpace core regions, driving incremental leverage.
- Guidance Raised: Supply chain gains, regulatory milestones, and pricing initiatives support a more confident 2023 outlook.
Business Overview
Artivion is a medical device company focused on cardiac and vascular repair, specializing in aortic stent grafts, mechanical heart valves, tissue processing, and surgical adhesives. The company generates revenue through proprietary platforms such as ONIX, BioGlue, and StentGrafts, with a business model centered on differentiated technology, regulatory expansion, and global commercial distribution. Major revenue segments include ONIX mechanical valves, stent grafts for aortic repair, tissue processing, and surgical adhesives, with an increasing presence in Asia Pacific and Latin America.
Performance Analysis
Artivion delivered 10% constant currency revenue growth in Q1, led by a 24% surge in ONIX platform sales and robust gains across BioGlue, StentGrafts, and tissue processing. Regional momentum was strongest in Asia Pacific and Latin America, which delivered 18% and 34% constant currency growth, respectively, outpacing North America and Europe. Gross margins improved sequentially, though remained below prior year levels due to inflationary pressure and product mix.
General and administrative expenses were elevated, reflecting non-recurring acquisition-related costs and increased commercial activity, but management expects a normalization in subsequent quarters. R&D spend fell as the company wound down the PROACT 10A trial, freeing capital for commercial initiatives. Adjusted EBITDA margin improved, with management reiterating its commitment to $75 million+ in 2024 adjusted EBITDA, underpinned by operating leverage and regional scale-up.
- ONIX Platform Drives Top-Line: ONIX’s 24% growth was broad-based, with double-digit gains in all geographies and continued market share capture.
- Emerging Markets Accelerate: APAC and Latin America’s growth outpaced core markets, with regulatory approvals and channel investments driving incremental volume and leverage.
- Margin Dynamics Mixed: Sequential margin improvement offset by inflation and mix, with future margin expansion expected from price increases and operational leverage.
Artivion’s ability to raise guidance reflects both strong execution and confidence in regulatory and supply chain catalysts unfolding through the remainder of 2023.
Executive Commentary
"Our strong performance was led by our ONIX platform, which grew 24%, followed by BioGlu at 8%, StentGraphs at 8%, and Tissue Processing at 7%, all compared to the first quarter of 2022 on a constant currency basis."
Pat Mackin, CEO
"Given our momentum in Q1, our price increase initiatives, anticipated improvement in supply of stent grafts, and anticipated FDA approval for per clot, we are raising our revenue guidance and now expect constant currency revenue growth of between 9% and 12% for the full year of 2023."
Ashley Lee, CFO
Strategic Positioning
1. Proprietary Platform Differentiation
Artivion’s ONIX mechanical valve, the only valve maintainable at a low INR (international normalized ratio, a measure of blood clotting), continues to drive global share gains and pricing power. Management highlighted that forthcoming price increases on proprietary devices have yet to be fully realized in reported results, signaling further upside potential.
2. Regional Expansion and Leverage
APAC and Latin America are now key growth engines, with regulatory approvals unlocking new markets and existing channel investments starting to deliver operating leverage. Management expects to achieve 25 to 30% annual growth in these regions through 2024, with incremental sales now outpacing incremental investment.
3. Regulatory and Pipeline Catalysts
Multiple regulatory milestones are on the horizon, including FDA approval for PERCLAW (surgical hemostatic powder) and ongoing PMA (premarket approval) trials for AMDS and Nexus stent graft systems. Successful completion of these trials could expand Artivion’s addressable market by $900 million in 2025, contingent on exercising the Endospan option.
4. Supply Chain and Manufacturing Optimization
Recent hiring in Germany has increased stent graft production capacity, with productivity improvements expected to accelerate revenue growth in the second half. Management anticipates these supply chain gains will further support top-line expansion and margin leverage.
5. Commercial Channel Discipline
Channel expansion is now focused and measured, with the U.S. and Europe largely at scale and APAC investments titrated to regulatory wins. This approach is expected to yield increased EBITDA leverage as more product flows through established infrastructure.
Key Considerations
Artivion’s Q1 demonstrated the compounding effect of proprietary technology, disciplined channel expansion, and regulatory progress. The company’s ability to drive growth while managing cost structure and capital allocation will be central to sustaining momentum.
Key Considerations:
- Pricing Power Emerging: Proprietary device price increases are expected to drive margin expansion in upcoming quarters, but are not yet reflected in results.
- Regulatory Milestones as Catalysts: Pending FDA approvals for PERCLAW and pipeline PMA trials represent both near- and long-term growth triggers.
- Operational Leverage Materializing: Channel and manufacturing investments are now yielding incremental revenue with lower incremental cost, especially in APAC and Latin America.
- Cost Structure Management: Elevated Q1 G&A is expected to normalize, with non-recurring items and front-loaded commercial activity unlikely to repeat at the same magnitude.
Risks
Inflationary pressures on materials and labor, as well as product and geographic mix, continue to weigh on gross margins. Regulatory delays or clinical trial misses could defer or eliminate anticipated market expansion. Debt levels remain elevated, though management asserts no near-term need for additional capital. Execution risk around price realization and channel productivity will be critical as the company seeks to translate top-line momentum into sustainable margin gains.
Forward Outlook
For Q2 and the remainder of 2023, Artivion guided to:
- Constant currency revenue growth of 9% to 12% (raised from 8% to 12%)
- Revenue range of $337 to $348 million (up from $331 to $343 million)
- Adjusted EBITDA minimum of $52 million (raised from $50 million)
For full-year 2023, management expects:
- Acceleration of revenue growth in the second half as German manufacturing productivity ramps
- Impact of price increases and regulatory approvals to strengthen top and bottom line
Management emphasized that price increases, regulatory catalysts, and channel leverage will support the path to $75 million+ in adjusted EBITDA for 2024, with no anticipated need for additional capital or credit facility draws.
Takeaways
Artivion’s Q1 performance and guidance raise validate the company’s strategy of leveraging proprietary technology and disciplined regional expansion.
- ONIX Platform and Emerging Markets: ONIX’s broad-based growth and APAC/LatAm acceleration are now central to both revenue and margin expansion, with pricing power and channel leverage set to build in 2023.
- Pipeline and Regulatory Upside: PMA trial progress and pending FDA approvals create optionality and potential for step-change in addressable market, with $900 million expansion possible in 2025.
- Margin and Capital Discipline: Management’s focus on operational leverage, normalization of G&A, and prudent capital allocation underpin the path to $75 million+ EBITDA and deleveraging.
Conclusion
Artivion’s Q1 results signal a business executing on multiple fronts—proprietary platform growth, emerging market expansion, and pipeline advancement. The raised outlook and management’s confidence in margin and cash generation position the company as a differentiated MedTech growth story for 2023 and beyond.
Industry Read-Through
Artivion’s experience underscores the value of proprietary technology and disciplined channel expansion in MedTech, especially as inflation and supply chain volatility persist. The company’s ability to raise prices on differentiated products before competitors, and to leverage regulatory wins for regional growth, offers a playbook for peers navigating similar macro and operational challenges. Emerging market investment, when tied to regulatory milestones, can yield rapid leverage and growth, a lesson relevant for other device makers with global ambitions. Finally, the focus on pipeline-driven market expansion highlights the increasing importance of clinical trial execution and regulatory agility for future MedTech value creation.